Oncopeptides Showcases Promising NK-Cell Engager Data for Multiple Myeloma at AACR 2026

Oncopeptides AB ( (SE:ONCO) ) has provided an announcement.

Oncopeptides AB announced that new preclinical data from its proprietary SPiKE platform, focusing on a novel bispecific NK-cell engager for multiple myeloma, has been accepted for presentation at the AACR Annual Meeting 2026 in San Diego. The study, conducted in collaboration with Eurostars-funded partners and Pharmatest Services, shows significant inhibition of tumor growth in a humanized multiple myeloma mouse model when the engager is combined with expanded adaptive NK cells.

Management highlights the data as strong preclinical proof-of-concept for redirecting the innate immune system by precisely targeting BCMA, aiming to address limitations and toxicities of current T-cell–directed therapies. The recognition by AACR and promising tumor cell lysis in disease-relevant models bolster Oncopeptides’ position in next-generation immuno-oncology and could enhance its long-term prospects in the relapsed or refractory multiple myeloma treatment landscape.

More about Oncopeptides AB

Oncopeptides AB is a Swedish biotech company specializing in targeted therapies for difficult-to-treat cancers, with a focus on research, development and commercialization. It leverages its proprietary Peptide Drug Conjugate and SPiKE platforms to deliver cytotoxic agents into cancer cells, and its flagship drug is commercialized in Europe with partnerships in South Korea, the Middle East, Africa and other regions.

Founded in 2000, the company employs about 80 people and operates in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed on Nasdaq Stockholm under the ticker ONCO, positioning it as a niche oncology player in the European biotech market.

Average Trading Volume: 2,897,932

Technical Sentiment Signal: Sell

Current Market Cap: SEK524.4M

Learn more about ONCO stock on TipRanks’ Stock Analysis page.